ATE535245T1 - Verwendung von mehrfach ungesättigten ketonen zur behandlung der psoriasis - Google Patents

Verwendung von mehrfach ungesättigten ketonen zur behandlung der psoriasis

Info

Publication number
ATE535245T1
ATE535245T1 AT03704739T AT03704739T ATE535245T1 AT E535245 T1 ATE535245 T1 AT E535245T1 AT 03704739 T AT03704739 T AT 03704739T AT 03704739 T AT03704739 T AT 03704739T AT E535245 T1 ATE535245 T1 AT E535245T1
Authority
AT
Austria
Prior art keywords
group
psoriasis
treat psoriasis
polyunsaturated ketones
hydrocarbon group
Prior art date
Application number
AT03704739T
Other languages
English (en)
Inventor
Berit Johansen
Marit Anthonsen
Wenche Sjursen
Anne Kristen Holmeide
Lars Skattebol
Original Assignee
Avexxin As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avexxin As filed Critical Avexxin As
Application granted granted Critical
Publication of ATE535245T1 publication Critical patent/ATE535245T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT03704739T 2002-01-29 2003-01-29 Verwendung von mehrfach ungesättigten ketonen zur behandlung der psoriasis ATE535245T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0202002.2A GB0202002D0 (en) 2002-01-29 2002-01-29 Use
PCT/GB2003/000364 WO2003063878A1 (en) 2002-01-29 2003-01-29 Use of polyunsaturated ketones for the treatment of psoriasis

Publications (1)

Publication Number Publication Date
ATE535245T1 true ATE535245T1 (de) 2011-12-15

Family

ID=9929945

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03704739T ATE535245T1 (de) 2002-01-29 2003-01-29 Verwendung von mehrfach ungesättigten ketonen zur behandlung der psoriasis

Country Status (14)

Country Link
US (4) US7687543B2 (de)
EP (1) EP1469859B1 (de)
JP (1) JP4608214B2 (de)
KR (1) KR100874505B1 (de)
CN (2) CN1678323A (de)
AT (1) ATE535245T1 (de)
AU (1) AU2003206999B2 (de)
CA (1) CA2473687C (de)
DK (1) DK1469859T3 (de)
ES (1) ES2378303T3 (de)
GB (1) GB0202002D0 (de)
NO (1) NO334413B1 (de)
PT (1) PT1469859E (de)
WO (1) WO2003063878A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2248798A1 (de) * 2009-05-08 2010-11-10 Pronova BioPharma Norge AS Neue Lipidverbindungen
GB0909643D0 (en) * 2009-06-04 2009-07-22 Avexxin As Glomerulonephritis treatment
CN102647984B (zh) * 2009-10-02 2015-03-25 埃维克辛公司 抗炎症的2-羰基噻唑和2-羰基恶唑
GB201014633D0 (en) * 2010-09-02 2010-10-13 Avexxin As Rheumatoid arthritis treatment
SG10201509127YA (en) 2010-11-05 2015-12-30 Pronova Biopharma Norge As Methods of treatment using lipid compounds
GB201205394D0 (en) 2012-03-27 2012-05-09 Adlens Ltd Improvements in or relating to deformable non-round membrane assemblies
GB201221329D0 (en) 2012-11-27 2013-01-09 Avexxin As Dermatitis treatment
CN105102438B (zh) 2013-01-29 2019-04-30 埃维克辛公司 抗炎症和抗肿瘤的2-氧代噻唑类和2-氧代噻吩类化合物
AR094941A1 (es) 2013-02-28 2015-09-09 Olaf Hustvedt Svein Una composición que comprende un compuesto lipídico, un triglicérido y un tensioactivo, y métodos para usarla
GB201313238D0 (en) 2013-07-24 2013-09-04 Avexxin As Process for the preparation of a polyunsaturated ketone compound
GB201409363D0 (en) * 2014-05-27 2014-07-09 Avexxin As Skin cancer treatment
GB201413695D0 (en) 2014-08-01 2014-09-17 Avexxin As Compound
GB201501144D0 (en) 2015-01-23 2015-03-11 Avexxin As Process for the preparation of a polyunsaturated ketone compound
CN107530306A (zh) 2015-04-28 2018-01-02 普罗诺瓦生物医药挪威公司 结构增强的含硫脂肪酸在预防和/或治疗非酒精性脂肪性肝炎中的用途
GB201604316D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
GB201604318D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
CN109310771A (zh) * 2016-06-03 2019-02-05 埃维克辛公司 包含多不饱和酮与皮质甾类化合物的联合疗法
KR20190013845A (ko) * 2016-06-03 2019-02-11 아벡신 에이에스 다중불포화 케톤 및 세코스테로이드를 포함하는 조합 치료요법
GB201609735D0 (en) * 2016-06-03 2016-07-20 Avexxin As Combination therapy
US20200323793A1 (en) * 2016-06-03 2020-10-15 Avexxin As Combination therapy comprising a polyunsaturated ketone and a calcineurin inhibitor
KR20190055153A (ko) 2016-09-21 2019-05-22 아벡신 에이에스 약학 조성물
AU2018285598B2 (en) * 2017-06-16 2021-11-11 Avexxin As Compositions and methods for treatment of a fibrotic disease
AU2018381124B2 (en) 2017-12-06 2024-06-27 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
GB201807892D0 (en) 2018-05-15 2018-06-27 Avexxin As Processes in the preparation of polyunsaturated ketone compounds
GB202020843D0 (en) 2020-12-31 2021-02-17 Coegin Pharma Ab Actinic keratosis treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09268153A (ja) 1996-04-02 1997-10-14 Sagami Chem Res Center トリフルオロメチルケトン誘導体及びホスホリパーゼａ２阻害剤
AU730364B2 (en) * 1997-09-23 2001-03-08 Bristol-Myers Squibb Company Selective cPLA2 inhibitors
JPH11199493A (ja) * 1997-11-13 1999-07-27 Nof Corp 皮膚外用剤組成物
WO2000002561A1 (en) * 1998-07-13 2000-01-20 University Of South Florida Modulation of the phospholipase a2 pathway as a therapeutic
US20020165119A1 (en) * 2001-01-31 2002-11-07 Alan Leff Method of treating inflammatory conditions by inhibiting cytosolic phospholipase A2
EP1243524A3 (de) * 2001-03-16 2004-04-07 Pfizer Products Inc. Pharmazeutisches Kit fÜr sauerstoffempfindliche Medikamente
US20040111957A1 (en) * 2002-12-13 2004-06-17 Filippini Brian B. Water blended fuel composition

Also Published As

Publication number Publication date
US7687543B2 (en) 2010-03-30
US20150202165A1 (en) 2015-07-23
ES2378303T3 (es) 2012-04-11
WO2003063878A1 (en) 2003-08-07
GB0202002D0 (en) 2002-03-13
CA2473687A1 (en) 2003-08-07
US20130324613A1 (en) 2013-12-05
US20050165116A1 (en) 2005-07-28
CN101849929A (zh) 2010-10-06
AU2003206999B2 (en) 2007-12-13
KR20040089127A (ko) 2004-10-20
US20100152293A1 (en) 2010-06-17
US8865768B2 (en) 2014-10-21
KR100874505B1 (ko) 2008-12-18
NO334413B1 (no) 2014-02-24
DK1469859T3 (da) 2012-03-19
JP4608214B2 (ja) 2011-01-12
JP2005518419A (ja) 2005-06-23
US8524776B2 (en) 2013-09-03
EP1469859A1 (de) 2004-10-27
US9375409B2 (en) 2016-06-28
NO20043548L (no) 2004-08-25
EP1469859B1 (de) 2011-11-30
PT1469859E (pt) 2012-03-06
CN1678323A (zh) 2005-10-05
CA2473687C (en) 2011-04-12

Similar Documents

Publication Publication Date Title
ATE535245T1 (de) Verwendung von mehrfach ungesättigten ketonen zur behandlung der psoriasis
DE60335997D1 (de) Lactoferrin-zusammensetzungen und verfahren zur behandlung von diabetischen ulcus
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
BRPI0006634B8 (pt) composição tópica compreendendo extrato de matricária no tratamento e prevenção de distúrbios inflamatórios
ATE462427T1 (de) Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
DE60026152D1 (de) Verwendung von stearidonsäure zur herstellung eines arzneimittels für die behandlung oder vorbeugung von krebs
DE602006020775D1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von manie und bipolaren störungen
ATE422357T1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
DE60112766D1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
BR0213100A (pt) Combinações para o tratamento de distúrbios imuniinflamatórios
ATE452884T1 (de) Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase
DE602004023762D1 (de) Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren
DE60011794D1 (de) Verwendung von docetaxel für die behandlung von hepatozelluläre krebs
ATE486612T1 (de) Verfahren zur behandlung von diabetes typ 2
ATE415965T1 (de) Verwendung von verzweigtkettigen fettsäuren und ihrer derivate zur schmerzbehandlung
DE60334094D1 (de) Verwendung von pleuromutilinen zur behandlung von erkrankungen, die durch helicobacter pylori verursacht werden
ATE206052T1 (de) Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
DE69324374T2 (de) Verwendung von kardiotonischen Mitteln und Inhibitoren der Stickstoffoxidsynthese zur Linderung von pathologisch verringertem Blutdruck
DE602004030661D1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
ATE315387T1 (de) Verwendung von substituierten 6- dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz
SE0301884D0 (sv) New use III
ATE361085T1 (de) Verwendung einer zusätzlich fermentierten getreideschlempe zur vorbeugung und/oder behandlung erhähter blutzucker-werte
DE60128084D1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl
ATE409469T1 (de) Verwendung von 2,2,3,3, tetramethylcyclopropane carbonsäure derivaten zur behandlung von psychiatrischen störungen
ATE288263T1 (de) Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis)